The FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List is the regulatory end of compounded GLP-1s from outsourcing facilities. The stated rationale is that no clinical need exists for 503B compounding when the branded products are commercially available. This episode breaks down what the proposal actually does, who it affects, and where the hard line between clinical need and economic need gets drawn.
Part I covers the 503B legal framework, the specific exclusion mechanism being used, and what the proposal means for the outsourcing facilities that built programs around compounded GLP-1 production during the shortage period. Part II examines the comment period dynamics, the litigation risk from affected parties, and the downstream effects on compounding pharmacies, telehealth prescribers, and the patients who were using compounded formulations for cost reasons rather than shortage reasons.
